introduct
develop
antivir
agent
treat
nonhiv
infect
larg
focuss
therapi
treatment
chronic
hepat
infect
b
c
nucleosid
analogu
continu
mainstay
hbv
therapeut
clinic
develop
sever
continu
last
year
seen
first
small
molecul
inhibitor
hcv
proteas
inhibitor
enter
phase
clinic
trial
produc
strike
reduct
viral
load
treat
individu
develop
first
hcv
replicon
system
applic
screen
antivir
agent
begin
provid
tangibl
benefit
disclosur
mechanist
structur
divers
hcv
inhibitor
remain
consider
interest
inhibitor
herp
simplex
human
cytomegaloviru
virus
particularli
nonnucleosid
compound
develop
area
respiratori
viru
inhibitor
focuss
respiratori
syncyti
viru
descript
first
antivir
activ
anim
model
follow
oral
administr
west
nile
viru
outbreak
us
origin
confin
east
coast
broaden
consider
summer
claim
live
wake
event
septemb
ilth
smallpox
promin
concern
potenti
agent
bioterror
develop
area
review
inhibitor
hepat
b
viru
hbv
adefovir
dipivoxil
ihepsera
approv
us
treatment
hbv
septemb
european
union
march
lth
provid
second
small
molecul
antivir
add
lamivudin
inject
protein
ifna
approv
agent
treat
hbv
infect
adefovir
effect
inhibitor
hbv
caus
mutat
revers
transcriptas
resist
adefovir
seen
week
monotherapi
clinic
studi
entecavir
z
current
undergo
trial
compar
dose
mgday
mgday
day
patient
previous
unrespons
treatment
compar
treatment
result
lower
overal
viral
load
lower
alt
level
higher
proport
patient
undetect
hbv
dna
level
moreov
advers
event
less
observ
separ
trial
treatmentna
patient
week
dose
mglday
show
reduct
viral
dna
level
independ
baselin
alt
level
treatment
result
loglo
reduct
hbv
dna
lnucleosid
repres
promis
area
antivir
research
ldt
telbivudin
current
clinic
trial
design
evalu
patient
safeti
efficaci
compar
standard
treatment
hbeag
recent
data
releas
trial
involv
adult
random
receiv
plu
monotherapi
daili
year
viral
load
reduct
greater
logto
seen
patient
studi
arm
contain
treatmentlimit
doserel
advers
event
report
mechan
action
lfmau
clevudin
fi
current
trial
firmli
understood
recent
molecular
dynam
simul
experi
suggest
triphosph
deriv
may
act
competit
inhibitor
rather
substrat
hbv
polymeras
lo
emtricitabin
coviraciltm
also
current
clinic
trial
treatment
hbv
nda
seek
approv
market
treatment
hiv
file
septemb
result
cli
zal
trial
elvucitabin
releas
hbv
treatmentna
patient
receiv
singl
daili
dose
mg
mean
declin
plasma
hbv
dna
loglo
observ
day
treatment
furthermor
plasma
level
excess
valu
wild
type
ymdd
mutant
achiev
low
dose
arm
therefor
anticip
efficaci
resist
infect
ongo
trial
mutat
aris
respons
therapi
found
precor
region
confer
hbeag
neg
major
metabolit
form
rat
human
serum
monoest
potent
hbv
inhibitor
ec
nm
postul
arylthio
moieti
respons
specif
toward
hbv
lower
cytotox
pmea
activ
compon
adefovir
dipivoxil
addit
analog
structur
class
prepar
phenylthioand
ether
show
promis
whilst
aromat
thioether
exhibit
higher
cytotox
nonnucleosid
inhibitor
hbv
begin
emerg
anticip
show
reduc
crossresist
nucleosid
analogu
b
close
analog
activ
wild
type
hbv
mutant
pm
cell
postul
interfer
packag
pregenom
viral
rna
result
inhibit
viral
revers
transcript
pyridinedicarboxamid
repres
first
report
nonnucleosid
inhibitor
hbv
revers
transcriptas
enantiom
q
activ
cell
cultur
appear
prevent
proper
format
viral
nucleocapsrd
inhibitor
hepat
c
viru
hcv
nearli
million
individu
infect
hepat
c
viru
hcv
worldwid
hcv
infect
respons
death
annual
unit
state
burden
expect
increas
significantli
second
pegyl
interferona
ifn
roch
pegasi
approv
mono
therapi
conjunct
ribavirin
copegustm
howev
safeti
concern
combin
therapi
remain
accumul
erythrocyt
lead
hemolyt
anemia
prompt
search
safer
interferon
cotherapi
includ
activ
enantiom
ij
levovirin
prodrug
viramidin
improv
liver
expens
erythrocyt
exposur
develop
safe
efficaci
hcvspecif
antivir
agent
remain
import
goal
develop
subgenom
hcv
replicon
dramat
enhanc
potenti
identifi
inhibitor
signific
advanc
toward
establish
correl
replicon
inhibit
clinic
efficaci
recent
accomplish
disclosur
preliminari
clinic
data
select
inhibitor
serin
proteas
hcv
structur
relat
highli
modifi
macrocyl
tripeptid
deriv
extrem
potent
vitro
k
valu
nm
nm
toward
hcvla
b
proteas
respect
figur
similar
potenc
observ
cell
cultur
cognat
hcv
replicon
nm
nm
respect
antivir
efficaci
establish
studi
conduct
patient
chronic
hcv
signific
liver
fibrosi
patient
treat
mg
po
bid
display
decreas
serum
hcv
rna
level
least
log
copiesml
two
day
treatment
four
patient
record
reduct
viral
load
order
magnitud
viral
titer
return
baselin
follow
cessat
therapi
drugrel
safeti
issu
identifi
intens
effort
devot
toward
discoveri
inhibitor
hcv
continu
focu
larg
peptidebas
molecul
requir
effect
complement
activ
site
proxim
region
proteas
crystal
structur
macrocycl
inhibitor
relat
bound
hcv
proteas
disclos
acycl
tripeptid
inhibitor
use
gener
resist
subgenom
replicon
mutat
map
proteas
amongst
sever
strategi
disclos
ctermin
carboxyl
peptid
inhibitor
may
replac
nacyl
sulfonamid
moieti
exemplifi
novel
approach
constrain
mimic
peptid
backbon
repres
macrocycl
tetrahydroindolizin
b
ic
pm
imidazolon
bicycl
prolin
deriv
k
pm
pm
inhibitor
construct
around
either
aketo
amid
boron
acid
moieti
wellpreced
serin
proteas
inhibitor
motif
engag
catalyt
serin
residu
coval
revers
interact
ph
howev
chemic
reactiv
prerequisit
potent
inhibit
peptid
background
sinc
phenethylamid
azapeptid
inhibit
hcv
ki
valu
pm
respect
activ
diastereom
ahydroxi
amid
element
explor
context
found
possess
configur
unanticip
explain
presenc
intramolecular
hydrogen
bond
orient
lipophil
moieti
isom
depict
nonpeptid
inhibitor
proteas
much
less
common
progress
made
direct
bicycl
lactam
mechanismbas
inhibitor
hcv
whilst
addit
exampl
bisbenzimidazol
deriv
reli
upon
zr
consolid
enzymeinhibitor
complex
describ
rna
polymeras
anoth
structurallycharacter
viral
protein
attract
target
therapeut
intervent
inhibitor
hcv
polymeras
broadli
divid
nucleosid
nonnucleosid
deriv
nucleosid
analog
ribavirin
ii
suggest
interfer
initi
elong
step
hcv
rna
replic
sever
hcv
inhibitor
incorpor
modifi
dribos
element
includ
deriv
pm
analog
ec
pm
cytidin
deriv
ego
pm
sever
nonnucleosid
inhibitor
hcv
report
includ
seri
phenylalanin
deriv
compound
k
fm
repres
compound
cocrystal
appear
bind
inact
open
conform
polymeras
almost
activ
site
scaffold
hcv
polymeras
inhibitor
discov
includ
amino
thiophen
repres
enol
rhodanin
pm
structur
variat
previous
disclos
benzimidazol
deriv
go
c
fm
claim
activ
replicon
mechanist
studi
benzo
thiadiazin
polymeras
inhibitor
suggest
interfer
initi
step
viral
rna
synthesi
allow
potenti
synergi
exist
elong
inhibitor
hcv
therapi
includ
block
viral
rna
intern
ribosom
entri
site
ire
bind
viral
envelop
glycoprotein
attach
highli
conserv
ire
target
oligonucleotid
artifici
ribozym
littl
progress
made
develop
small
molecul
inhibitor
clinic
evalu
antisens
oligonucleotid
reveal
logto
reduct
plasma
hcv
rna
level
approxim
patient
week
treatment
anoth
approach
may
prove
complementari
virusspecif
hcv
therapi
induct
interferon
product
host
cell
small
molecul
act
via
tolllik
receptor
activ
identifi
activ
immun
respons
rna
interfer
rnai
rapidli
emerg
technolog
proven
power
mean
select
control
protein
product
cell
cultur
inhibit
hcv
replic
replicon
accomplish
use
procedur
whilst
demonstr
select
target
liver
protein
fa
vivo
use
rnai
hold
promis
treatment
hcv
maribavir
demonstr
viva
antihcmv
activ
dosag
regimen
test
mg
tid
mg
bid
mean
reduct
semen
hcmv
titer
loglo
pfulml
hcmv
serin
proteas
perceiv
attract
antivir
target
recent
crystal
structur
data
demonstr
signific
conform
flexibl
bind
pocket
protein
complex
two
peptidomimet
inhibtor
seri
franslactam
repres
pm
respect
deriv
structur
platform
hcv
inhibitor
inhibit
hcmv
serin
proteas
excel
select
mechanist
studi
consist
acyl
activ
site
serlz
hcmv
proteas
revers
timedepend
manner
chap
nonhiv
antivir
agent
meanwel
et
al
one
current
licens
drug
avail
treat
hsv
act
inhibit
viral
dna
polymeras
provid
suitabl
backdrop
emerg
resist
viru
rational
identifi
inhibitor
viral
protein
two
group
report
novel
thiazolecontain
inhibitor
hsv
helicaseprimas
bay
lead
preclin
candid
potent
nm
antiherpet
current
use
treat
hsv
infect
murin
lethal
challeng
model
protect
edso
valu
mglkg
compar
much
higher
dose
mglkg
respect
requir
acyclovir
show
efficaci
addit
patent
applic
extend
promis
chemotyp
appear
second
seri
hsv
helicaseprimas
inhibitor
bs
repres
disclos
bil
bs
inhibit
viral
growth
nm
display
excel
therapeut
index
reduc
cutan
genit
diseas
murin
model
treatment
initi
hour
postinfect
interestingli
treatment
initi
hour
infect
reduc
patholog
mortal
mgkglday
compar
acyclovir
untreat
anim
seri
deriv
potent
broad
spectrum
nonnucleosid
inhibitor
dna
polymeras
herpesviru
famili
includ
hcmv
vzv
subject
number
recent
disclosur
compound
exhibit
signific
inhibitori
activ
toward
human
ci
effect
antivir
cell
cultur
potent
inhibit
hcmv
ec
pm
vzv
ec
pm
hsv
pm
activ
toward
ganciclovirand
cidofovirresist
hcmv
acyclovirresist
hsv
excel
oral
bioavail
protect
effect
murin
cmv
anim
model
also
report
seri
relat
analog
report
recent
patent
literatur
pyrazolopyridin
deriv
report
possess
activ
vero
cell
fm
structur
relat
irnidazopyridin
deriv
activ
hsv
type
e
pm
potent
inhibitor
hcmv
nm
appear
act
step
viral
replrcat
preced
dna
polymer
overview
respiratori
virus
continu
signific
sourc
mortal
morbid
annual
death
rate
due
influenza
us
estim
doubl
last
year
attribut
age
popul
studi
also
reveal
greater
appreci
contribut
respiratori
syncyti
viru
mortal
recent
discov
human
metapneumoviru
hmpv
identifi
signific
caus
wheez
infant
influenza
inhibitor
oseltamivir
tamiflutm
approv
treatment
influenza
adult
children
prevent
adult
adolesc
european
commun
june
consolid
posit
market
lead
neuraminidas
na
inhibitor
howev
develop
third
neuraminidas
inhibitor
peramivir
termin
biocryst
june
disappoint
result
oral
bioavail
compound
fail
meet
key
efficaci
endpoint
reduc
time
onset
relief
symptom
march
outbreak
sever
acut
respiratori
syndrom
sar
emerg
southeast
asia
culprit
quickli
identifi
new
coronaviru
distinct
previous
identifi
human
coronaviru
influenza
continu
chimer
virus
contain
na
ml
ion
channel
show
suscept
oseltamivir
amantadin
rimantadin
respect
vitro
viva
role
na
inhibitor
pandem
influenza
review
identif
structur
novel
na
inhibitor
continu
substitut
primari
amin
moieti
oseltamivir
vinyl
group
afford
potent
influenza
b
na
inhibitor
ki
nm
addit
sar
studi
around
zanamivir
focuss
hydroxyl
replac
f
methyl
afford
potent
na
inhibitor
icso
valu
nm
respect
compar
favor
nm
prototyp
polymer
analogu
zanamivir
link
polyglutam
backbon
via
posit
show
enhanc
influenza
inhibitori
activ
compar
monoval
analogu
omethyl
analogu
zanamivir
claim
protect
mice
lethal
influenza
infect
follow
oral
administr
prodrug
g
whilst
bicycl
ether
first
zanamivir
deriv
demonstr
oral
efficaci
mous
model
optim
screen
lead
potent
cyclopentanebas
inhibitor
neuraminidas
use
combin
structurebas
design
combinatori
chemistri
describ
detail
mechanismbas
inhibitor
hrv
cystein
proteas
probe
use
combin
structurebas
design
principl
parallel
synthesi
method
effort
find
less
peptid
inhibitor
chroman
emerg
inhibitor
replic
cell
cultur
nm
howev
serotyp
coverag
compound
poor
much
reduc
potenc
subtyp
observ
ration
context
structur
data
hrv
cystein
proteas
releas
viral
polyprotein
cleav
ci
tram
fashion
releas
protein
also
proteolyz
host
cap
bind
complex
order
compromis
host
cell
transcript
seri
nphenyl
pyrazol
deriv
claim
inhibitor
essenti
enzym
effect
antivir
agent
cell
cultur
pm
iim
hrv
rnadepend
rna
polymeras
potenti
drug
discoveri
target
clone
express
purifi
e
coi
shown
enzymat
activ
inhibitor
resdiratotv
svncvtial
viru
rsv
role
rsv
morbid
mortal
continu
focu
research
design
provid
accur
perspect
viru
mediat
signific
diseas
burden
enhanc
awar
rsv
stimul
interest
viru
therapeut
target
recent
emerg
new
structur
class
inhibitor
howev
clinic
proofofprincipl
remain
establish
rsv
antivir
viropharma
suspend
develop
rsv
fusion
inhibitor
examin
topic
administ
agent
benzimidazol
describ
first
rsv
inhibitor
demonstr
antivir
activ
anim
model
follow
oral
administr
mechan
action
studi
indic
g
inhibitor
fusion
viral
host
cell
membran
target
rsv
f
fusion
protein
analogu
form
basi
proprietari
claim
whilst
trimeri
disclos
seri
benzimidazolebas
inhibitor
rsv
fusion
repres
seri
activ
cell
cultur
ego
ngml
coronavirus
envelop
singlestrand
positivesens
rna
virus
commonli
associ
respiratori
infect
man
two
coronavirus
underli
caus
approxim
upper
respiratori
tract
infect
usual
mild
moder
sever
gener
recogn
common
cold
although
immunocompromis
popul
coronaviru
infect
lead
pneumonia
howev
march
outbreak
sever
acut
respiratori
syndrom
sar
emerg
southeast
asia
quickli
spread
countri
carri
larg
air
travel
sar
infect
document
worldwid
within
follow
month
associ
substanti
morbid
includ
fever
nonproduct
cough
malais
chill
headach
dyspnea
signific
mortal
death
report
whilst
sar
appear
origin
southern
china
novemb
report
major
outbreak
hong
kong
toronto
canada
march
brought
diseas
world
promin
attribut
modern
technolog
commun
intern
teamwork
led
rapid
isol
sequenc
viru
caus
sar
identifi
novel
coronaviru
littl
similar
previous
known
human
coronavirus
final
confirm
came
demonstr
infect
monkey
sar
produc
syndrom
ident
seen
man
viru
could
subsequ
recov
experi
rapidli
follow
develop
diagnost
assay
base
realtim
quantit
pcr
method
taqman
protocol
transmiss
sar
appear
via
personperson
contact
infect
droplet
rather
airborn
possibl
fecalor
rout
inhibitor
coronavirus
larg
unknown
although
treatment
ribavirin
oseltamivir
examin
empir
fashion
scope
mosquitoborn
west
nile
viru
outbreak
us
broaden
consider
summer
extend
almost
state
caus
case
enceph
death
viru
present
sever
convent
protein
target
suitabl
intervent
includ
protein
express
serin
proteas
helicas
nucleosid
triphosphatas
activ
rnadepend
rna
polymeras
moreov
screen
use
cell
cultur
assay
provid
panopli
less
well
understood
target
howev
potent
select
wnv
inhibitor
describ
date
ribavirin
ii
inhibit
wnv
rna
product
oligodendrogli
cell
human
neural
cell
line
fm
nucleosid
analogu
interfer
helicas
activ
wnv
pm
similarli
potent
antivir
cell
cultur
inhibitor
vaccinia
viru
smallpox
smallpox
arous
consider
concern
discuss
promin
focuss
potenti
agent
bioterror
mani
inhibitor
vaccinia
viru
replic
interfer
host
cell
pathway
includ
inosin
monophosph
dehydrogenas
cyclopentenyl
nucleosid
analogu
neplanocin
sadenosylhomocystein
hydrolas
pyrazofurin
omp
decarboxylas
dine
cytidin
analogu
neplanocin
equal
potent
inhibitor
sever
orthopox
virus
includ
smallpox
complement
el
mrna
start
codon
hpv
demonstr
efficaci
two
anim
model
current
undergo
clinic
evalu
fuse
tetracycl
amid
g
claim
inhibit
bind
papilloma
viru
el
dna
cntrcal
step
viral
replic
j
nm
vaccin
deriv
viruslik
particl
complet
prevent
incid
cervic
neoplasia
young
women
impress
result
provid
strong
encourag
develop
vaccin
spectrum
addit
encompass
broader
rang
hpv
respons
major
cervic
cancer
combin
multival
vaccin
base
selfassembl
viruslik
particl
direct
toward
recogn
enter
trial
rn
chem
